Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $16.75.

Separately, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN raised its position in shares of Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after acquiring an additional 3,139 shares during the period. Deutsche Bank AG increased its stake in Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the period. Rhumbline Advisers boosted its position in shares of Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock worth $108,000 after purchasing an additional 5,008 shares in the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC boosted its position in shares of Alto Neuroscience by 1.5% during the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after purchasing an additional 6,663 shares in the last quarter.

Alto Neuroscience Stock Up 0.6 %

Shares of Alto Neuroscience stock opened at $2.71 on Friday. The firm’s 50-day moving average price is $3.63 and its two-hundred day moving average price is $6.05. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1-year low of $2.58 and a 1-year high of $18.35.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. On average, sell-side analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.